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1. Introduction
1.1. Osteogenesis Imperfecta (OI)
“Fragile bones” have been described in medical literature for centuries. Osteogenesis imper‐
fecta (OI), whose name means “imperfect birth of bones”, is one such fragile bone syn‐
drome. A generalized disorder of the body’s connective tissue, it is most obvious in its
effects on the bone, but also involves the body’s ligaments, tendons, fascia, eyes, skin, teeth
and ears. It is a highly variable heritable disorder characterized by recurring bone fractures,
low bone mass and bone fragility [1]. Bone fragility has led to the common name “brittle
bone disease” for OI. Its overall incidence is approximately one in 10,000 births. The inci‐
dence of forms of OI recognizable at birth is 1/16-20,000, with about equal incidence of mild
forms that are not recognizable until later in life. The clinical range of this condition is ex‐
tremely broad, ranging from cases that are lethal in the perinatal period to cases that maybe
difficult to detect and can present as early osteoporosis [2]. Individuals with OI may have
varying combinations of growth deficiency, defective tooth formation (dentinogenesis im‐
perfecta), hearing loss, macrocephaly, blue coloration of sclerae, scoliosis, barrel chest and
ligamentous laxity. In more severe cases, people are susceptible to fracture from mild trau‐
ma and even from acts of daily living.
1.2. Classification and types of OI
Classical OI is an autosomal dominant condition caused by defects in type I collagen, the
major structural component of the extracellular matrix of bone, skin and tendon. This defi‐
ciency arises from an amino acid substitution of glycine to bulkier amino acids in the colla‐
gen triple helix structure. The larger amino acid side-chains create steric hindrance that
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creates a bulge in the collagen complex, which in turn influences both the molecular nano‐
mechanics as well as the interaction between molecules, which are both compromised [3].
As a result, the body may respond by hydrolyzing the improper collagen structure. If the
body does not destroy the improper collagen, the relationship between the collagen fibrils
and hydroxyapatite crystals to form bone is altered, causing brittleness. Another suggested
disease mechanism is that the stress state within collagen fibrils is altered at the locations of
mutations, where locally, larger shear forces lead to rapid failure of fibrils even at moderate
loads as the homogeneous stress state found in healthy collagen fibrils is lost [3]. In the past
several years, autosomal recessive forms of OI have been identified. Although recessive OI
is not due to defects in collagen, its etiology in a collagen-modification complex is collagen-
related. Hence, in ~10% of cases, genes encoding proteins involved in type I collagen’s com‐
plex posttranslational modifications and intracellular trafficking can also be involved in the
causation of OI [4]. Autosomal recessive OI is caused by defects in two of the components of
the prolyl 3-hydroxylation complex, which modifies the α1(I) chain of collagen in the endo‐
plasmic reticulum, cartilage-associated protein (CRTAP) [5, 6] and prolyl 3-hydroxylase
(P3H1) [7]. OI can also occur as a consequence of mutations in key osteoblast genes that
code for proteins involved in matrix homeostasis [8, 9] and are not directly related to colla‐
gen metabolism and matrix structure. About 5% of OI cases are not caused by defects of
type I collagen or the P3H1 hydroxylation complex and their etiology is presently unknown.
Most people with OI receive it from a parent but in 35% of cases it is an individual (de novo
or "sporadic") mutation.
1.3. Sillence classification
Classical OI is generally described using the Sillence classification, a nomenclature based on
clinical and radiographic features, which was first proposed in 1979 [10]. This classification
subdivides patients into four types based on disease severity and progression:
Type I OI, the most common and mildest form of the disease and is caused by a quantitative
defect with synthesis of structurally normal type I procollagen at about half the normal
amount [11]. Type I OI is non-deforming and results in patients attaining close to normal
height, however vertebral fractures are common and can lead to mild scoliosis. Joint hyper‐
extensibility is also a common feature. Growth deficiency and long bone deformities are
generally mild. In these patients, fractures are rare at birth but begin with ambulation [1].
Patients also present with blue sclera and 50% may have hearing loss. Type I has been divid‐
ed into A and B subtypes based on the absence or presence of dentinogenesis imperfecta, a
genetic disorder of tooth development also known as hereditary opalescent dentin. This
condition causes teeth to be discolored (most often a blue-gray or yellow-brown color) and
translucent. Teeth are also weaker than normal, making them prone to rapid wear, break‐
age, and loss. These problems can affect both primary teeth and permanent teeth.
Type II OI is the most severe OI form, generally resulting in death in the perinatal period,
although survival up to one year has been noted. These patients exhibit multiple intrauter‐
ine rib and long bone fractures and severe skeletal deformities, which eventually result in
respiratory failure. Legs are usually held in a frog leg position with hips abducted and knees
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flexed. The skull is severely under mineralized with wide open fontanels. The bones of these
infants are predominantly composed woven bone without haversian canals and organized
lamellae. In 1984 a radiological sub classification of type II OI was proposed [12]: OI II A—
broad ribs with multiple fractures, continuous beaded ribs, severe undermodeling of femur;
OI II B—normal/thin ribs with some fractures, discontinuous beaded ribs, some undermod‐
eling of femur; OI II C—varying thickness of ribs, discontinuous beading of ribs, malformed
scapulae and ischiae, slender and twisted long bones.
Type III OI is a severe form of the disease, characterized by severe progressive skeletal de‐
formities. This is due to the synthesis of mutated collagen. Fractures may be present in utero
and are very common during the growth period as the bones are extremely fragile. The inci‐
dence of fracture remains high even in the adult life. The long bones are soft and deformed
from normal muscle tension. Individuals are severely short statured and scoliosis can lead to
respiratory problems. These patients also present with dentinogesisimperfecta. Radiograph‐
ically, metphyseal flaring and “popcorn” formation at growth plate is seen. These patients
require intensive physical rehabilitation to attain assisted ambulation.
Type IV OI is the most clinically diverse group of patients of OI. The phenotype can vary
from mild to severe. Scleral hue is also variable. Typically, these patients suffer several frac‐
tures in a year and present with bowing of long bones. While fractures decrease after puber‐
ty, individuals have a short final stature. Radiographically, the patients have osteoporosis
and mild modeling abnormalities. Like type I OI, this group can also be divided into two
subgroups on the basis of the presence or absence of dentinogenesis imperfecta[13]. It is
from this heterogeneous group that types V, VI and VII have been identified based on dis‐
tinct clinical and histological features [14-16].
Although type V to VIII continues the Sillence classification, they are based on different cri‐
teria than other types. Type V and VI are defined using bone histology and have a pheno‐
type that would be included in type IV. However, these individuals do not have defects in
type I collagen. Type VII and VIII are recessive forms whose phenotype overlaps type II and
III. These patients have deficiencies of components of collagen modification complex in en‐
doplasmic reticulum.
Type V OI is moderately deforming and there are three distinctive features: the frequent de‐
velopment of hypertrophic calluses at the fracture site, the calcification of interosseous
membranes between the bones of the forearm and the presence of radio-opaque metaphy‐
seal band immediately adjacent to the growth plate on X-rays [14]. The calcified inteross‐
eous membrane severely limits the pronation/supination of the hand and may lead to
secondary dislocation of the radial head. These patients have normal teeth and white scler‐
ae. Patients with type V OI represent 4-5 % of the OI population seen the hospital.
Type VI OI also presents with moderate to severe deformities and do not have blue sclera
and dentinogenesis imperfecta. Distinctive histiological features are the fish-scale like ap‐
pearance of the bone lamellae and presence of excessive osteoid accumulation on bone form‐
ing surfaces. Inheritance is autosomal dominant and may represent approximately 4% of
moderately to severely affected parents [15].
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Type VII OI is an autosomal recessive form caused by defects in CRTAP, cartilage-associated
protein [16]. Patients have moderate to severe skeletal deformities, bone fragility, lack of
blue sclera and no dentinogenesis imperfecta. The distinctive clinical feature is the rhizomel‐
ic shortening of the humerous and femur. To date, this disorder has only been observed in a
community of Native Americans in northern Quebec [16].
Type VIII OI is an autosomal recessive form caused by defects in prolyl 3-hydroxylase 1
(P3H1, encoded by LEPRE1). P3H1 forms a complex in the endoplasmic reticulum with
CRTAP. This causes a phenotype which overlaps types II and III OI but has distinct features,
including white sclera, extreme growth deficiency and under mineralization [7].
1.4. Dominantly inherited OI
Most patients with OI (~ 90%) have mutations in one of the type I collagen genes, COL1A1
or COL1A2. These mutations are dominantly inherited and the phenotype can vary from the
very mild to lethal. There are two general cases of mutation in Type I collagen genes that
result in OI: those that cause a quantitative defect with synthesis of structurally normal type
I procollagen at about half the normal amount and those that result in synthesis of structur‐
ally abnormal collagen. The former is usually due to premature termination codons in one
COL1A1 molecule that initiates decay of the mRNA from the affected allele. This generally
results in mild nondeforming phenotype with blue sclera (Type I OI) [11]. The most preva‐
lent mutation results in substitution of one of the invariant glycine residues that have a criti‐
cal role in helix formation. A collagen type I molecule comprises a triple helix made up of
two alpha 1 and one alpha 2 polypeptide chains. In the center of each helical turn, i.e. every
third amino acid is a glycine residue, which is essential for the structure of the molecule.
Any substitution of the residues can result in structural abnormalities and produce a mix‐
ture of normal and abnormal collagen strands. Depending on the substitution type and loca‐
tion, the phenotype can vary from mild to very severe. Usually, patients with the more
severe type of the disease have a mutation at one essential glycine residue site [17]. Altera‐
tions in collagen type I molecules lead to structural changes in the bone and the abnormal
collagen has lower tensile strength. This leads to the brittleness of the bones in OI. OI not
only results in low trabecular bone mineral density and thin cortices, but also in small, slen‐
der bones. Together, these factors contribute to the fragility of the bones.
1.5. Recessively inherited OI
In the past decade, the genetic basis of 10 new OI variants has been discovered, seven of
which result from mutations in genes encoding proteins involved in the post translational
modifications of type I procollagen [6, 7, 18-22]. In 2007, mutations in CRTAP were identi‐
fied in patients without mutations in COL1A1 and COL1A2 but with excess posttranslation‐
al modification of type I collagen indicative of delayed folding of the triple helix [6, 7].
Patients with similar phenotype with mutations in genes such as LEPRE1 (proyl 3-hydroxy‐
lase, P3H) and PPIB (Peptidyl-prolylcis-trans isomerase B;cyclophilin B) have also been
identified [19, 20]. FK binding protein 10 (FKBP10) mutations present as a milder phenotype
in late childhood or adolescence with long bone fracture, acetabular protrusion and scoliosis
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[22]. Among the most recent discoveries are the association of mutations in the gene SER‐
PINF1 (serpin peptidase inhibitor, clade F) with type VI OI [23]. The latter two are proteins
responsible for chaperoning collagen through the endoplasmic reticulum. SERPINF1 enco‐
des pigment epithelium derived factor, a secreted glycoprotein with uncertain function in
bone. Mutations in LRP5, a key regulator of osteoblast function, affects bone accrual during
growth [8]. More recently, a child with moderate OI phenotype has been identified with ho‐
mozygous mutation in SP7, which codes for osterix, a transcription factor specifically ex‐
pressed in osteoblasts in the developing skeleton [9].
2. Animal models used for the study of OI
The many different types and subtypes of OI highlight the importance of developing animal
models to study the disease. Canine, feline, bovine and ovine models of OI have been descri‐
bed (reviewed in [24]). However, the majority of animal studies have been conducted using
engineered and spontaneously occurring murine models.
2.1. Mov-13 mouse: A model for OI type I
In Mov-13 mice, transcription of the proα1(I) gene was completely blocked as a result of Mo‐
loney leukemia virus integration at the 5’ end of the gene [25]. No functional α2(I) was de‐
tected in embryos [26], likely as a result of rapid degradation of proα2(I) procollagen chains
which are unable to form stable triple helices. Mice homozygous for the null mutation pro‐
duced no type I collagen and died at mid-gestation while heterozygotes survived to young
adulthood [27]. Heterozygotes produced 50% less type I collagen which causes progressive
hearing loss and alterations in the mechanical properties of long bones [28]. The heterozy‐
gous Mov-13 mouse therefore serves as a model for type I OI. As many as 5% of osteoblasts
from long bones were shown to produce normal amounts of type I collagen, thus implying
that a small set of osteoblasts did not express the mutant phenotype [29]. This bone tissue
mosaicism for expression of the mutant allele may explain why Mov-13 heterozygotes do
not display an obvious bone fragility phenotype.
2.2. Brittle II mouse: A model for type II OI
The cre/lox recombination system was used to develop a lethal murine knock in model of OI
type II [30]. A 3.2 kbp transcription/translation stop cassette was introduced in intron 22 and
flanked by directly repeating lox recombination sites. After homologous recombination in
ES cells, two male chimeras were obtained. A knock in mouse carrying and intronic inclu‐
sion was generated by mating chimeras with wild-type females. Alternatively splicing in‐
volving the stop cassette resulted in retention of non-collagenous sequences. This mouse
had the lethal phenotype of the similar human mutation and was designated BrtlII. Skeletal
staining showed rib fractures, poor skeletal mineralization and shorter vertebral bodies. The
mice die a few hours after birth from apparent respiratory distress.
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2.3. Oim/Oim mouse: A model for type III OI
Chipman et al. [31] described a strain of mice with a nonlethal recessively inherited muta‐
tion that resulted in phenotypic and biochemical features that simulate moderate to severe
human OI. This oim mutation arose spontaneously in 1985 in the Mutant Mouse Resource of
The Jackson Laboratory. It has since been determined that the underlying defect in the oim
mouse is a mutation in COL1A2 [32]. This mutation changes the reading frame at the 3’ end
of the mRNA causing synthesis of an altered C-propeptide that ultimately inhibits the asso‐
ciation of these molecules into heterotrimeric type I procollagen bundles in the bone matrix.
Instead, homotrimers are formed which interferes with the integrity and quantity of the os‐
teoid that accumulates in the bone. This mouse model has been shown to have a phenotype
similar to that seen in human type III OI, including a decreased body size, abnormal bone
mineralization (contributing to the brittleness of the bones), decreased bone density and a
fragile skeleton susceptible to fractures. While the skeleton becomes progressively deformed
with age, homozygous mice can live a normal life span. The heterozygous mice simulate the
mild form of the disease in which the bones show abnormal cortical morphology and re‐
duced bone mechanical strength even though no fractures are seen. Heterozygote oim/+
mice have subtle skeletal fragility whereas homozygous oim/oim mice have marked skeletal
fragility. The dental phenotype in oim/oim is more severe in incisors than in molars and in‐
cludes changes in pulp chamber size, tooth shape, and dentin ultrastructure. Teeth in
oim/oim animals are clinically fragile. Although oim/+ teeth are grossly normal, ultrastruc‐
tural abnormalities such as reduction in the number and regularity of spacing of the denti‐
nal tubules, less mineralization, and blurring of the boundary between peritubular and
intertubular dentin can be found in oim/+ teeth [33].
Breeding studies showed that the oim mutation was inherited in most crosses as a single re‐
cessive gene on chromosome 6, near the murine COL1A2 gene. Biochemical analyses of skin
and bone, as well as isolated dermal fibroblast cultures, demonstrated that α1(I) homotrimer
collagen accumulated in these tissues. Short labeling studies in fibroblasts demonstrated an
absence of proα2(I) collagen chains. Nucleotide sequencing of cDNA encoding the COOH-
propeptide revealed a G deletion at proα2(I) nucleotide 3983; this results in an alteration of
the sequence of the last 48 aminoacids. Normal-sized mRNA is transcribed, but no secreted
protein has been identified in oim/oim fibroblasts and osteoblasts. Collagen from the
oim/oim mouse showed reduced resistance to tensile stress [34]. Neutron activation analyses
demonstrated that oim/oim femurs had significant differences in magnesium, fluoride, and
sodium content compared to wild type mouse femurs [35]. These and other studies suggest
that the known decreased biochemical properties of oim/oim bone reflect both altered min‐
eral composition and decreased bone mineral density, which further suggests that the pres‐
ence of α2(I) chains plays an important role in bone mineralization [36].
2.4. Brittle IV mouse: A model for type IV OI
The cre/lox recombination system was used to develop a nonlethal knock-in murine model
for OI [30]. A moderately severe OI phenotype was obtained from anα1(I) 349 Gly→ Cys
substitution in type I collagen, which is the same mutation in a type IV OI child. These mice,
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designated as Brittle IV (Brtl IV), have phenotypic variability ranging from perinatal lethali‐
ty to long-term survival with reproductive success. The size of Brtl IV mice was about 50%
that of normal littermates at 6 weeks of age, after which their size increased to about 80% of
normal. Deformity of the rib cage was apparent and both forelegs and hindlegs were bowed
and thinner than those of control littermates. The Brtl IV mouse has the molecular, biochem‐
ical, and radiographic features of human OI type IV. Heterozygous mutant mice have the
undermineralization of the skeleton, the bone fragility, and the deformity characteristic of
human patients. Their growth pattern, with normal size at birth followed by growth defi‐
ciency until 4–5 weeks of age, resembles the early childhood growth pattern reported for
moderately severe OI patients. However, no significant deformities in long bones were evi‐
dent in mutant mice after puberty and long bone fractures were also infrequent in adult
mice.
3. Therapies for OI
At present, there is no cure for OI; however, some ‘symptomatic’ treatment options are
available. The management of OI includes multidisciplinary input with experienced medi‐
cal, orthopedic, physiotherapy and rehabilitation specialties. The current goals of therapy
for OI are: to decrease the incidence of fractures; to increase growth velocity; to decrease
pain; to have a positive effect on bone metabolic markers, bone histomorphometry and bone
mineral density; and finally, to increase mobility and independence.
During past decades, various pharmacological agents have been administered to patients
with OI and the majority of them initially claimed beneficial results, although none proved
effective in controlled trials [37]. Among these were anabolic steroids, vitamin D, vitamin C,
sodium fluoride, magnesium oxide, flavonoids (catechin) and calcitonin. Until 18 years ago,
calcitonin was the most common therapy for OI, although its beneficial effects during the
clinical course of the disease were disputed in the literature [38]; however it is no longer
used. Thus, the search for effective treatments for OI remains ongoing.
3.1. Drug therapies
3.1.1. Bisphosphonates
In the last decade, the potential of bisphosphonate (BP) treatment has caused great excite‐
ment in the OI patient community and has generated new therapeutic options. BPs have
been accepted as the standard of care for children with OI and in particular with moderate
to severe forms of OI. The BP compounds are analogs of pyrophosphate which, when ad‐
ministered either orally or parentally, are characterized by a rapid and strong binding to hy‐
droxyapatite crystals in the bone mineral. Once BPs are buried in the skeleton they are
released only when bone is destroyed in the course of bone turnover. The success of BP ap‐
pears to be related to the unremitting osteoclastic activity. These agents are potent inhibitors
of bone resorption, decreasing osteoclast activity and number, although some effect on bone
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formation also occurs [39]. The potent anti-resorptive properties of BP inhibit the normal re‐
modeling activity that acts to renew and repair bone. This activity results in improved verte‐
bral shape and mass, higher cortical width, increased cancellous bone volume and
suppressed bone turnover as shown by histomorphometric studies [40]. The net effect is to
promote bone mineral accretion and at the same time to reduce bone turnover. Although the
quality of the new bone that is formed remains unchanged, the bones benefit from greater
mechanical strength due to overall increased bone mass [17].
A number of prospective studies have now shown that BPs can reduce fracture frequency,
increase bone mineral content and improve the radiographic assessment of bone shape in
growing children [41, 42]. In addition, linear growth is not impaired and fractures heal at
their expected rate. Increase mobility was reported in the two largest studies conducted [42].
Muscle force measured by maximal isometric grip force of the non-dominant hand showed
significant increases with BP therapy which was maintained for two years [43]. Patients with
OI types I, II and IV showed significant improvement in height after four years of BP thera‐
py [44]. It is difficult to assess the fracture rates as with increased mobility there might be a
transient increase in fractures. However, overall decrease in fracture rate has been demon‐
strated after therapy when compared to historical controls [42]. Bone mineral density in the
lumbar vertebrae also shows a rapid increase [45]. Radiographically, cycles of BP therapy
leave dense sclerotic bands at the metaphysis of long bones which may contribute to the in‐
creased strength of the bones [46]. However, questions remain as to the selection of patients
for treatment, which BPs to use, the minimum effective dose, the minimum effective treat‐
ment interval, appropriate duration of treatment and the role of oral BPs.
Concerns also remain regarding the potential buildup of microcracks and calcified cartilage
which could lead to poor bone healing and increase fragility [47]. Osteonecrosis of the jaw is
a complication of poor soft tissue and bone healing associated with BP therapy. While this is
mainly reported in elderly patients with cancer who have been given very high doses of BP
[48], there are concerns whether this complication could arise with long-term use of BP in
children. However, the greatest concern in children with OI is over suppression of bone
modeling and remodeling and worsening of bone quality. Long-term treatment, even at
standard doses, interferes with bone remodeling and can be detected as metaphyseal under-
tubulation [49, 50]. Reports from surgeons describe treated bone as “rock-hard” and “crum‐
bly”, providing insight into paradoxical increases in fractures in some treated patients.
Long-term suppression of bone turnover leads to accumulated micro-damage (microcracks)
in bone [51] that may underlie the decrease in material strength. The equivocal improve‐
ment in fractures in children is illuminated by data from BP treatment of the Brtl mouse [52].
Treatment increases bone volume and load to fracture of murine femora, but concomitantly
decreases material strength and elastic modulus. Femurs become, ironically, more brittle af‐
ter prolonged treatment and bands of mineralized cartilage create matrix discontinuities
that decrease bone quality. Prolonged treatment also alters osteoblast morphology. BP are
also buried in the skeleton where they have a half-life of many years, so long term side ef‐
fects may still surface. Thus, long-term use of BPs may not be beneficial as they decrease ma‐
terial properties and have detrimental effects on osteoblasts and bone formation.
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3.1.2. Growth hormone
In mild forms of OI, agents increasing the production of type I collagen may have a thera‐
peutic role. Growth hormone (GH) action positively affects bone growth and bone turnover
by stimulating osteoblasts, collagen synthesis and longitudinal bone growth [53]. GH has a
positive action on collagen metabolism, stimulating the expression in osteoblast cultures of
insulin like-growth factor-1 (IGF-1) and IGF binding protein-3, which in turn regulate the
synthesis of type I collagen [54, 55]. Osteoblasts from various species have IGF-I receptors
and respond to both endogenous and exogenous IGF by accelerating the proliferation and
increasing DNA and collagen synthesis [56, 57]. Animal studies in the oim/oim mouse model
of OI, with bone phenotype comparable to a mild form of OI in humans, showed that sys‐
temic GH injections [58] or GH transgene expression in marrow [59] increased spine and fe‐
mur length, produced significant changes in densitometric parameters and ameliorated
biomechanical structural properties of bone. There is limited literature regarding GH in OI
as only a few human studies have been performed using GH in patients with OI [60, 61].
One of the first attempts to treat OI with GH was more than 20 years ago by Kruse and Kuh‐
lencordt[62], who treated two patients affected by OI with GH. The patients had an increase
in periosteal new bone formation and in intracortical bone resorption with enhanced osteo‐
blastic activity [62]. Following these results, no further study was reported in the literature
until Marini and colleagues published their preliminary results from a limited number of
patients treated with GH or clonidine (a pituitary GH secretagogue) [60]. In a further study
by this group, the authors concluded that there is a group of type IV OI children who would
benefit from GH treatment in terms of linear growth, bone matrix synthesis and bone histo‐
morphometric parameters [63]. During GH therapy, patients have an improvement in gen‐
eral wellbeing, muscular performance and motor ability, which increases physical activity
and, consequently, fracture risk in some cases [64]. In a study examining the efficacy of one
year of GH treatment in patients affected by type I OI with an ascertained quantitative de‐
fect in type I collagen synthesis, GH treatment showed a positive effect on bone turnover,
markers of bone apposition (i.e., osteocalcin and procollagen type I carboxy terminal pro‐
peptide levels) and bone mineral density, while the fracture risk did not change [65]. Thus,
the results indicate that this is a useful therapy in patients with moderate forms of OI (the
majority of type I and a good proportion of type IV). Patients with pre-existing scoliosis or
bone deformities must be treated with particular caution because of the potential risk of
worsening of these problems. Therefore, the selection of patients for GH treatment should
be done carefully. It is possible that GH may be of benefit in combination with BP therapy
[65, 66], but this has still to be adequately investigated [63].
3.1.3. Parathyroid hormone
Parathyroid hormone (PTH) also has anabolic effects on the bone and has been shown to
have a positive effect for treatment of osteoporosis. Animal studies have shown that daily
injection of recombinant human PTH results in increased bone mass, substantial new bone
formation and altered bone architecture [67]. Based on this, daily injections of PTH should
be beneficial in OI. However, these animal studies have demonstrated that sustained deliv‐
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ery in young rats resulted in development of bone lesions and tumors [67]. Due to this pro‐
posed increased risk for development of osteosarcoma, PTH is currently not recommended
for children.
3.1.4. RANKL inhibitors
The potential therapeutic effects of receptor activator of nuclear factor kappa B ligand
(RANKL) inhibitors in OI are currently under investigation. A recent study in a mouse mod‐
el of OI (oim/oim) compared the effects of BP and RANKL inhibition. They found that al‐
though there were subtle differences between the two treatments, one was not superior to
the other. There were similar decreases in fracture incidence with increases in metaphyseal
bone volume via increase number of thinner trabeculae. BPs have the disadvantage of per‐
sisting in the bone for decades. Therefore RANKL inhibition is a newer, though more expen‐
sive treatment option, but may be preferred by some families and doctors as it is not
deposited in the bone matrix. However, studies are needed to optimize the age of onset of
therapy and the dose in children [68].
3.1.5. Bortexomib
The proteasome inhibitor Bortezomib is widely used in the treatment of multiple myeloma
[69] and has been demonstrated to have an osteoblastogenic affect on adult murine and hu‐
man mesenchymal stem cells by stabilizing RUNX-2 and acting directly on type I collagen
[70]. It enhances osteoblast activity, differentiation [71] and also number [72]. Using the Brtl
mouse model for OI, impairment in the differentiation of the progenitor cells towards osteo‐
blasts has been demonstrated [73]. Treatment of the Brtl mice with Bortexomib rescued the
osteoblastogenic capacity in vitro and ameliorated the bone properties in vivo, thus potential‐
ly identifying a new target for OI pharmacological treatment [73].
3.1.6. Sclerostin
A very recent study has investigated the potential of treating OI with antibodies to sclero‐
stin, an anabolic bone agent produced by osteocytes that negatively regulated bone forma‐
tion [74]. Antibodies to sclerostin are thought to stimulate osteoblasts and this agent is
currently in clinical trials for treatment of osteoporosis [75]. Using the Brtl/+ mouse model,
Sinder et al [74] demonstrated that treatment of OI mice for two weeks with antibodies to
sclerostin stimulated bone formation, improved bone mass and increased bone load and
stiffness to those of wildtype mice. These studies suggest short-term treatment of OI patients
with sclerostin antibody may lead reduced fractures and improved bone quality.
3.2. Cell-based therapies
Normal bone responds to fracture or loading by increasing bone resorption and formation
[76]. In a similar way, the OI bone initiates a cycle of bone remodeling in an attempt to form
a stronger matrix. However, in OI, mutant collagen is synthesized, secreted from the cell
and incorporated into matrix, where it actively participates in weakening the structure. Giv‐
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en the high turnover of bone seen in OI [77, 78], it is feasible that the deleterious effects in OI
could be reduced or neutralized by the presence of normal osteoprogenitor cells. Thus, the
potential to correct OI may lie in replicating the natural example of carriers, who have a sub‐
stantial proportion of cells heterozygous for the collagen mutation, but are clinically normal.
Studies of osteoblasts from carriers of type III and IV OI have shown that 40-75% of cells are
mutant, setting the threshold for minimal symptoms at 30-40% normal cells [79]. Based on
these findings, approaches that either target cells to suppress expression of mutant collagen
or replace mutant cells with donated bone cell progenitors have potential to serve as long-
term treatment for OI.
3.2.1. Gene-targeting therapy
While drug-based therapies may result in a more functional life for patients with moderate
to severe OI, gene therapies aimed at correcting or replacing the defective gene may poten‐
tially provide long-term reversal of symptoms. Antisense technologies to inactivate mutant
mRNA have been proposed as a method for mutation suppression [80]. In fibroblasts de‐
rived from a patient with type IV OI, antisense oligonucleotides were shown to suppress
mutant protein α2(I) mRNA to 50% and mutant α2(I) mRNA to 40% [80]. While promising,
these oligonucleotides also targeted the normal allele mRNA, suppressing it to 80% of its
level in control cells, rendering this therapy ineffective. Similar studies have tested the abili‐
ty of allele-specific suppression of mutant collagen expression by hammerhead ribozymes
(short RNA molecules with catalytic potential) to biochemically transform the recipient from
type II, III or IV OI into type I OI, in which individuals have a null allele, make half the nor‐
mal amount of collagen and have mild disease [81]. These findings show that this suppres‐
sion was complete and specific in vitro and substantial (50%) and highly selective (90%) in
cells. However, the successful application to animal models is still to be tested.
Another approach involves gene targeting of mutant COL1A1 and COL1A2 using adeno-vi‐
ral vectors in adult mesenchymal stem cells (MSCs). Two studies have shown successful
production of normal collagen cells targeted with a COL1A1 or COL1A2 mutation [82, 83].
In a recent study by Deyle et al [84], MSCs were isolated from OI patients and mutant colla‐
gen genes were inactivated by adeno-virus-mediated gene targeting. Induced pluripotent
stem cells (iPSC) were then derived from these gene-targeted cells with a floxed, polycis‐
tronic reprogramming vector, all vector-encoded transgenes were deleted with Cre recombi‐
nase. These iPSCs were then differentiated into mesenchymal and osteogenic cells in vitro,
which produce bone in vivo after transplantation into the subrenal capsule of immunodefi‐
cient mice. These approaches could be potentially valuable for individuals with OI who are
past early childhood. However, issues with low targeting success and random integration
need to be solved before these approaches can be validated in humans.
3.2.2. Cellular replacement therapy
A number of reports in literature using animal models have suggested that bone marrow
(BM) cells could be transplanted via the circulatory system and that the transplanted cells
contribute to skeletal tissues including bone [85, 86]. Also encouraging have been transplan‐
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tation studies of adult BM into Brtl pups in utero [87]. Despite low engraftment in bone (~
2%), transplantation eliminated the perinatal lethality of Brtl mice and improved the biome‐
chanical properties of femora in two-month old treated Brtl mice [87]. Current dogma sug‐
gests that BM contains two types of stem cells, mesenchymal stem cells (MSCs) and
hematopoietic stem cells (HSCs), and that their repertoire of differentiation/reconstituting
potentials are distinct and separate from each other. MSCs are defined by their adherence to
plastic and potential to differentiate into mesenchymal tissue cells such as bone, fat, muscle,
cartilage and fibroblasts [88-91]. The term “MSC” has been applied to define both mesenchy‐
mal stem cells and mesenchymal stromal cells [89]. HSCs are defined by their capability of
hematopoietic reconstitution in vivo and have also been shown to give rise to a few tissue
cell types including mast cells and osteoclasts. However, recent studies have begun to ques‐
tion the distinction between the potentials of MSCs and HSCs, particularly with regard to
osteo-chondrogenic tissues.
4. MSC-based therapy
Transplantation studies using murine models have evaluated the potential of MSCs to di‐
rectly differentiate into osteogenic cells to treat OI [92, 93]. Studies in a mouse model of OI
showed that infusion of marrow stromal cells (MSCs) resulted in a significant increase in
collagen production [85]. The data presented by Wang et al [92] demonstrated that murine
MSCs migrate and incorporate into the developing neonatal heterozygous and homozygous
OI mice, differentiate into osteoblasts and appear to participate in the bone formation of the
recipient mouse in vivo. A recent study from the same group evaluated green fluorescent
protein (GFP)-expressing single cell expanded, marrow-derived progenitors for engraftment
in a neonatal model of OI following systemic transplantation [93]. Tissues from the recipient
mice were examined at two and four weeks post transplantation. Their study shows that the
progenitors infused in the neonatal OI mice engraft in the various tissues including bones,
undergo differentiation, deposit matrix and form bone in vivo. The authors also state that the
progenitor cell transplantation is more efficient in developing OI mice than adult mice [93].
Cell therapy protocols also involve direct delivery of cells into target tissues with the hope
that the cells will differentiate into cells of the target tissues and repair or regenerate host
tissues. Li et al (2010) have demonstrated that MSCs infused into femurs of the oim/oim
mouse model contribute to bone formation in vivo. Improvement in mechanical properties of
the recipient bones seen may be the result of bone deposition by both endogenous and do‐
nor cells or paracrine actions of donor cells. The recipient mice were followed for six weeks
following cell infusion into femurs. It still remains to be investigated if this positive effect
lasts beyond this time period.
Intrauterine transplantation of fetal human MSCs was shown to markedly reduced fracture
rates and skeletal abnormalities in an oim/oim mouse model [94]. In a similar model, Van‐
leene et al [95] showed that human fetal MSCs isolated based on their adherence to plastic,
transplanted in utero in oim/oim mice migrated to bone, differentiated into mature osteo‐
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blasts, and expressed the missing protein COL1a2, altering the apatite mineral structure and
increasing bone matrix stiffness. The changes in microscopic material properties and micro‐
architecture contribute to the mechanical integrity of the bone, making the bone less brittle
and resulting in a decreased incidence of fracture. However, further work needs to be done
to investigate strategies to maximize donor cell homing to bone, differentiation, and colla‐
gen expression to maximize the therapeutic effects of transplantation.
While these studies suggest a role for MSCs in generation of osteogenic cells, the difficulty
in defining and isolating MSCs as well as the sometimes complex history of manipulation
before being tested for differentiation potentials in vivo, makes it difficult to determine the
mechanism by which these cells have an effect [89, 96, 97].
5. HSC-based therapy
Recent studies have identified a population of circulating human osteoblastic cells which ex‐
press osteocalcin or alkaline phosphatase and increase during pubertal growth and during
fracture repair [98]. Studies showed that these osteocalcin positive cells were able to form
mineralized nodules in vitro and bone in vivo. This population was subsequently shown to
be CD34+ [99], suggesting that it is derived from the HSC. In support of this, Chen et al [100]
have shown that the frequency of osteoblast progenitor cells is higher in CD34+ cells (ap‐
proximately 1/5000) than in CD34- population (1/33,000) of human BM. Murine transplanta‐
tion studies have demonstrated that transplantation of 3000 side population (SP) cells that
are highly enriched for HSCs generated osteoblasts in vivo [101]. In another study, Dominici
et al [102] transplanted marrow cells that had been transduced with GFP-expressing retrovi‐
ral vector and observed a common retroviral integration site in clonogenic hematopoietic
cells and osteoprogenitors from each of the recipient mice. This is consistent with observa‐
tions that non-adherent BM cells, the fraction enriched for HSCs, give rise to bone in culture
[101, 103]. A study of the kinetics and histological/anatomic pattern of osteopoietic engraft‐
ment after transplantation of ~ two million GFP-expressing non-adherent BM cells in 6-8
week old FVB/N OI mice revealed that osteopoietic engraftment was maximum two weeks
after transplantation [104]. However, this osteogenic engraftment decreased to negligible
levels after six months to one year while the hematopoietic reconstitution remained stable
over the entire period of observation [104]. The authors explain the lack of durable donor
derived osteopoiesis by the intrinsic genetic program or the external environmental signals
that suppress the differentiation capacity of the donor stem cells. Studies in both an animal
model and patients (CT NCT00187018) demonstrated that the non-adherent bone marrow
population was able to significantly and robustly provide osteoprogenitors for treatment of
OI [105]. Together, these studies provide compelling evidence for the existence of a common
progenitor cell with both hematopoietic and osteocytic differentiation potentials in the non-
adherent or CD34-expressing, HSC-enriched, fraction of BM cells.
In the last decade, many conflicting reports have been published regarding tissue-reconsti‐
tuting ability of HSCs. To determine the tissue reconstituting potential of HSCs, we have
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carried out a series of studies based on BM reconstitution by a single HSC (reviewed in
[106-108]). These studies have shown that transplantation of a clonal population derived
from a single HSC expressing transgenic enhanced GFP (EGFP) results in efficient genera‐
tion of mice exhibiting high-level, multi-lineage engraftment from a single HSC. In this
model, putative HSCs are sorted based on surface marker expression and Hoechst dye ef‐
flux (side population, SP), identified by combining single cell deposition with short-term
culture and functionally defined in vivo by the ability to reconstitute the BM when a single
cell is transplanted into lethally irradiated mice [109-112]. It is important to note that there is
no equivalent test for defining a MSC, making it difficult to isolate and characterize MSCs
[96, 97]. Findings from studies using a single cell/clonal cell transplantation method have
shown that HSCs can give rise to non-hematopoietic cells such as fibroblasts and fibrocytes
[109], tumor-associated fibroblasts/myofibroblasts [110], valve interstitial cells [113], glomer‐
ular mesangial cells [111], brain microglial cells and perivascular cells [112], inner ear fibro‐
cytes [114], retinal endothelial cells [115] and epithelial cells in multiple organs [116]. Most
recently, our lab has demonstrated that HSCs give rise to adipocytes [117], a cell also
thought to be of mesenchymal origin, and osteo-chondrogenic cells [118].
Based on these findings, we hypothesized that the primary defect in OI may lie in the HSC.
As the bone turnover is high in OI, introduction of the normal progenitor cells would quick‐
ly populate the bone with cells making normal matrix and therefore ameliorate and/or pre‐
vent the occurrence of associated pathologies. To test this hypothesis, we conducted HSC
transplantation in a mouse model of OI (oim/oim) [119]. In these studies, recipient oim/oim
mice were first scanned by micro-computed tomography (micro-CT) before transplantation
to obtain baseline images and information on bone histomorphometrics. The BM of lethally
irradiated oim/oim mice was then reconstituted with EGFP+ non-adherent mononuclear cells
or purified HSCs from EGFP mice. Transgenic EGFP+ mice (C57BL/6) [120] which ubiqui‐
tously express EGFP under the control of the actin promoter were used as BM donors for
transplantation into homozygous OI mice (oim/oim; B6C3Fe a/a-Col1a2oim/J; Jackson Labs).
Either 2 x105 mononuclear cells or 50 Lin- Sca-1+ c-kit+ CD34- SP cells (putative HSCs) pre‐
pared from the EGFP mice were injected via tail vein into irradiated oim mice. The mice
transplanted with 50 Lin- Sca-1+ c-kit+ CD34- SP cells also received injection of 2 x 105 un-ma‐
nipulated BM cells from an oim/oim mouse which served as radio-protective cells during the
post radiation pancytopenia period. Oim/oim mice with no engraftment and irradiated
oim/oim mice transplanted with 2 x 105 MNCs from another oim/oim mouse were used as con‐
trols. Changes in bone parameters were analyzed using longitudinal micro-CT. To confirm
participation of HSC-derived osteoblasts and osteocytes in oim/oim bones, the EGFP+ cells
were analyzed in paraffin sections.
Dramatic improvements in bone architecture were observed in the 3D micro-CT images of
bones of HSC-engrafted oim mice at three, six and nine months post-transplantation which
correlated with high levels of hematopoietic engraftment. These improvements correspond‐
ed to improvements in histomorphometric parameters including an increase in bone vol‐
ume, trabecular number, thickness and density and a decrease in trabecular spacing.
Decrease in trabecular pattern factor indicated an improvement in the connectivity and
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structure of the trabeculae.In addition to quantifiable improvements in the bone architec‐
ture, we also observed clinical improvements in the engrafted oim/oim mice. The weight of
the mice increased over the course of the experiment, perhaps in part due to the dramatic
improvements in the bone architecture and density. The mice also became more active and
were less prone to fractures during routine bedding changes and animal husbandry. In con‐
trast to the mice engrafted with normal HSCs, the bone architecture and clinical parameters
in the control mice continued to deteriorate over the course of the experiment. Analysis of
paraffin sections showed the presence of numerous EGFP+ cells within the bone (unpublish‐
ed data) that expressed Runx-2 and osteocalcin, demonstrating that they were osteoblasts
and osteocytes as well as their origin from the HSCs. Studies are under way to determine
the mechanisms by which HSCs affect structural and clinical improvements in the OI model.
6. Clinical bone marrow transplantations
Together, these preclinical studies suggest a potential for bone marrow transplantation in
treating osteopoietic disorders. Findings from these studies are consistent with clinical trans‐
plantation of whole BM or fractionated MSCs in children with severe form of OI. In the first
trial, three children with OI were transplanted with un-manipulated BM from a sibling do‐
nor [121]. Three months after osteoblast engraftment, specimens from trabecular bone show
evidence of new dense bone formation. There was an increase in the total body bone mineral
content associated with increase in growth velocity and reduced frequency of fracture [121].
Similar results were seen in an additional study with five children with severe OI [122].
With extended follow-up, the patients’ growth rates either slowed down or plateaued, but
bone mineral content continued to increase. These finding suggest a durable engraftment of
osteogenic donor cells, which could potentially convert a severe clinical phenotype to a less
severe one. Due to the promising results obtained with the previous trials, a study was con‐
ducted where gene marked, donor marrow derived mesenchymal cells were used to treat
six children with severe OI. The cells engrafted in the bone, marrow stroma and skin and
produced clinically measurable benefits in the form of increase growth velocities. But sur‐
prisingly, no increase was observed in the total body bone mineral content [123]. An addi‐
tional study of a single human fetus receiving in utero transplantation of fetal MSCs reported
that very low engraftment (0.3%) could still be demonstrated in bone at nine months of age,
however evaluation of clinical outcome was complicated by treatment in infancy with bi‐
sphosphonate [124]. While statistical significance in these studies was often lacking because
of the small number of patients in each study, these findings nonetheless suggest beneficial
clinical effects of BM transplantation in OI.
7. Conclusions and future perspectives
There is significant interest in the use of BM transplantation to repair various tissues as illus‐
trated by many ongoing clinical trials (reviewed in [89, 125]). Several preclinical studies
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have suggested that transplantation of BM cells may lead to improvements in other genetic
diseases that involve collagen synthesis such as Alport syndrome [126, 127] and Epidermol‐
ysis bullosa [128]. As detailed above, preclinical studies and those in patients also demon‐
strate a therapeutic role for BM transplant for OI. Despite these studies, the mechanism by
which marrow transplant ameliorates the genetic disorder remains unclear. Given that the
BM is thought to contain two stem cell populations, MSCs and HSCs, elucidation of the
stem cell with osteogenic potential would potentially drive therapies for OI. Our studies
demonstrate that the HSC has this potential [118, 119] and can correct the osteogenic defect
in an animal model of OI [119]. Our findings are supported by a recent study that compared
the mechanisms of action for non-adherent mononuclear cells and MSCs in OI [105]. In this
study, it was shown that both non-adherent BM cells enriched for HSCs and MSCs are clini‐
cally effective agents for cell therapy of bone, but that the two populations function by dis‐
tinct mechanisms. Non-adherent BM cells were found to directly differentiate into
osteoblasts and secrete normal collagen to the bone matrix. In contrast, MSCs did not en‐
graft in the bone, but secreted soluble mediators that indirectly stimulated growth. Togeth‐
er, these studies demonstrate the potential for stem cell-based therapies for long-term
treatment of OI. However, several issues remain to be elucidated including: what is the opti‐
mal delivery schedule, which type of cell to deliver for greatest efficacy (MSC, HSC or com‐
bination), and how to expand their potential with adjunct drug therapy.
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